Kraft Heinz, Lyft fall premarket; CVS Health, DoorDash and Restaurant Brands rise

Published 2025-02-12, 08:02 a/m
© Reuters.

Investing.com -- U.S. stock futures slipped marginally lower Wednesday, as investors awaited the release of key inflation data that could guide future Federal reserve policy.

Here are some of the biggest premarket US stock movers today:

  • Kraft Heinz (NASDAQ:KHC) stock fell 4.6% after the packaged foods giant forecast annual profit below estimates, as it contended with sluggish demand for its higher-priced products.

  • CVS Health (NYSE:CVS) stock rose 12% after the pharmacy chain reported fourth-quarter revenue and profit that topped estimates, even as its troubled insurance business continued to see higher medical costs.

  • Restaurant Brands (TSX:QSP_u) (NYSE:QSR) stock rose 4.1% after the holding company topped market expectations for quarterly revenue, helped by strong demand for value meals at its Burger King chain and strength in its Tim Hortons coffee outlets.

  • Lyft (NASDAQ:LYFT) stock slumped over 13% after the ride-hailing company forecast current-quarter gross bookings below estimates.

  • DoorDash (NASDAQ:DASH) stock soared 6.2% after the food delivery company reported better-than-expected revenue for the fourth quarter after the previous close.

  • Super Micro Computer (NASDAQ:SMCI) stock gained 10% despite the server maker cutting its annual revenue forecast, adding that it believes it will be able to file delayed annual and quarterly reports with the Securities and Exchange Commission by Feb. 25, after being accused by short seller Hindenburg Research of "accounting manipulation" in August.

  • Gilead Sciences (NASDAQ:GILD) stock climbed 4.6% after the biopharmaceutical firm’s fourth-quarter results surpassed expectations on both the top and bottom lines.

  • Barrick Gold (NYSE:GOLD) stock rose 0.8% after the world’s second-largest gold miner beat expectations for fourth-quarter profit on higher gold prices and production.

  • Biogen (NASDAQ:BIIB) stock fell 0.9% after the drugmaker forecast 2025 profit below expectations, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.